Product NewsLife Sciences

Transcreener CD73 assay: Leveraging nucleotide detection to measure adenosine

7 Jun 2020
Transcreener CD73 assay: Leveraging nucleotide detection to measure adenosine

Watch this webinar from Meera Kumar, Senior Scientist at BellBrook Labs, to learn more about CD73 as a target for immunotherapy, including information on how the transcreener CD73 assay was developed and how this assay can be used to help measure adenosine.

Assay Development Services

BellBrook Labs

BellBrook Labs delivers bespoke assay development and lead discovery solutions using its Transcreener® HTS platforms. Their expert team optimizes detection of small-molecule modulators for enzyme targets—tailoring buffer, enzyme, and detection conditions to yield strong initial-velocity signals (Z’ 0.7–0.9) in just 2–4 weeks.

(2)

Transcreener® ADP² Kinase Assays

BellBrook Labs

The Transcreener® ADP² Kinase Assay Kit universally detects ADP produced by any kinase or ATPase using a direct mix‑and‑read format, eliminating coupling steps. Available in FP, FI, and TR‑FRET formats with far‑red tracers to minimize interference, it's HTS-ready across 96‑, 384‑, and 1536‑well plates with robust Z' ≥ 0.7 performance.

(3)

Transcreener® AMP²/GMP² Phosphodiesterase Assays

BellBrook Labs

The Transcreener® AMP²/GMP² Phosphodiesterase Assay Kit directly detects AMP or GMP produced by PDEs, ligases, synthetases, ENPP1, and related enzymes using a mix‑and‑read FP or TR‑FRET format—no coupling steps needed. Compatible with 1–1000 µM native substrates, it delivers excellent HTS performance (Z’ ≥ 0.7, ≥100 mP shift) in a one-step, far‑red fluorescence assay.

(2)

Other videos from BellBrook Labs

Links

Transcreener CD73 assay: Leveraging nucleotide detection to measure adenosine